IMM-101 is under clinical development by Immodulon Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect IMM-101’s likelihood of approval (LoA) and phase transition for Metastatic Pancreatic Cancer took place on 17 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IMM-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

IMM-101 overview

IMM-101 is under development for the treatment of metastatic pancreatic cancer, metastatic melanoma, pancreatic ductal adenocarcinoma, metastatic colorectal cancer and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for the prevention of the COVID-19 associated infections and severe respiratory infections in cancer patients at increased risk of exposure. It is administered intradermally as a suspension. IMM-101 is a vaccine that comprises of heat killed whole cell mycobacterium from a strain of Mycobacterium obuense. It was also under development for the treatment of breast cancer, lung cancer, leiomyosarcoma, dedifferentiated liposarcoma and cholangiocarcinoma

Immodulon Therapeutics overview

Immodulon Therapeutics (Immodulon) is a biopharmaceutical company that develops novel immunotherapeutic products for cancer. The company lead product such as IMM-101 and IMM-201. Its IMM-101 is a heat killed whole cell mycobacterium’s intradermal formulation which helps to provoke delayed hypersensitivity response. It provides conducts clinical study to evaluate the safety and tolerability of intradermal IMM-101 in adult melanoma cancer patients. Immodulon also develops immunotherapeutic options as adjunctive therapy for certain cancers. The company has ongoing collaborations for the use of mycobacterial immunomodulators in the treatment of persistent chronic inflammation such as mood disorders, tuberculosis, post traumatic stress disorder, and others. Immodulon is headquartered in Uxbridge, the UK.

Quick View IMM-101 LOA Data

Report Segments
  • Innovator
Drug Name
  • IMM-101
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.